DRUG USE EVALUATION OF CHILDREN WITH GLOMERULONEPHRITIS INONE OF HOSPITALS IN BANDUNG

• Main Author: Hasanah, Hani
• Format: Theses
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/45368
• Institution: Institut Teknologi Bandung

Glomerulonephritis is a kidney patophysiology process with the general etiology of the impairment of immunological mechanism, where normal kidney dysfunction occured, especially in kidney glomerular. It comes as an acute or chronic state characterized by nephritic syndrome with inflammation lesion and nephrotic syndrome with proteinuria. A not-well treated chronic glomerulonephritis will become a risk factor for the kidney failure End Stage Renal Disease (ESRD). The aim of this research was to examine the medication treatment of the glomerulonephritis with acute nephritic syndrome and glomerulonephritis with nephritic syndrome in a way of healing and prevention of the deterioration of the kidney damage into an ESRD kidney failure, such as by doing a drug use evaluation in glomerulonephritis with acute nephritic syndrome patients and glomerulonephritis with nephritic syndrome patients. Then, the pharmacoeconomy analysis of the patients’s drug treatment is also observed. This research was done by a retrospective and concurrent method with a medical record and patients’s medication card data collection from the glomerulonephritis with an acute nephritic syndrome patient and glomerulonephritis with nephrotic syndrome and also some interview with the patients. The retrospective research was done in the period of 2011 of hospitalized patients and the concurrent research was done in the period of December 2012 –February2013. The most common used drug groups as the first line therapy for the acute nephritic syndrome patients were diuretic (17.8% and 47.4%) and antibiotic (15.3% and 28.6%), and for the nephrotic syndrome patients were corticosteroid (33.3% and 35.2%) and antineoplastic (21.6% and 22.1%). The appropriate drug choice in the acute nephritic and nephrotic syndrome patients was generally appropriate regarding to the patient’s clinical condition and diagnoses (88.9% and 100% in ANS patients and 100% in NS patients) with the appropriate doses found higher in the ANS patients (76.3% and 94.8%) than the NS patients (76% and 76,7%). The drug interaction in both ANS and NS patients showed the bigger occurance in the concurrent analysis (18.2% ANS and 19% NS) than the retrospective analysis (11.8% ANS and 0% NS), but it was not statistically significant with the iv significance score at 0.731. The adverse events were also analyzed more in the concurrent analysis (18.8% ANS and 47.6% NS) than the retrospective analysis (22.2% ANS and 5% NS), with the significance score at 0.012 (statistically significant) indicated that the adverse event analysis was more suitable to be done concurrently which allows to analize not only from the patient’s medical records, but also intervense by having a discussion with patients and medical colleague.